Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Lays out Roadmap for 2021

Stockhouse Editorial January 7, 2021

Algernon Pharmaceuticals Announces Plans for 2021

GlobeNewswire January 7, 2021

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

GlobeNewswire December 30, 2020

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire December 24, 2020

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

GlobeNewswire December 23, 2020

Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

GlobeNewswire December 21, 2020

Algernon Provides New Info on COVID Study

Stockhouse Editorial December 17, 2020

Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data

GlobeNewswire December 17, 2020

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire December 16, 2020

IIROC Trade Resumption - AGN

Canada NewsWire December 15, 2020

Algernon Announces Positive Trending Interim Data for COVID Study

Stockhouse Editorial December 15, 2020

Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study

GlobeNewswire December 15, 2020

IIROC Trading Halt - AGN

Canada NewsWire December 14, 2020

Algernon Pharmaceuticals Enrolls Final Patient in Human Study for COVID-19 Treatment

Stockhouse Editorial November 30, 2020

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire November 30, 2020

Algernon Pharmaceuticals Announces 154 Patients Enrolled in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire November 23, 2020

Australian Clinical Research Grants Algernon $600k Tax Credit

Stockhouse Editorial November 16, 2020

Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research

GlobeNewswire November 16, 2020

Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire November 13, 2020

Algernon to Provide Interim Data from COVID-19 Human Study

Stockhouse Editorial November 9, 2020